Financials

  • Market Capitalization 133.38 M
  • Employee 112
  • Founded 1999
  • CEO Jacqueline Shea
  • Website www.inovio.com
  • Headquarter Delaware, United States
  • FIGI BBG000BK6YX5
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-0.96
Price to sales ratio
1 248.52

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
3786
CNTB
Connect Biopharma Holdings Limited - American Depositary Shares
2.23 USD-2.19%-5.51%+8.78%+8.78%140.43 M USD
3811
HURA
TuHURA Biosciences, Inc. - Common Stock
2.11 USD-0.94%+0.48%0.00%-21.56%134.46 M USD
3831
BDTX
Black Diamond Therapeutics, Inc. - Common Stock
2.23 USD-1.76%+0.45%+32.74%-17.71%128.12 M USD
3833
VANI
Vivani Medical, Inc. - Common Stock
1.42 USD+1.43%+1.43%+10.94%+24.56%128.09 M USD

Frequently asked questions about Inovio Pharmaceuticals, Inc.

What is the Inovio Pharmaceuticals, Inc. stock price today?

The current price of Inovio Pharmaceuticals, Inc. (INO) is 1.29. Over the past 24 hours, the stock has changed by +2.38%. Follow the INO chart for real-time price dynamics.

What is the stock ticker of Inovio Pharmaceuticals, Inc.?

Inovio Pharmaceuticals, Inc. trades under the ticker INO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Inovio Pharmaceuticals, Inc. stock going up?

INO has changed by +8.40% over the last week, +76.71% over the last month, and -45.11% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Inovio Pharmaceuticals, Inc.?

Inovio Pharmaceuticals, Inc. currently has a market capitalization of 133.38 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Inovio Pharmaceuticals, Inc. earnings last quarter?

Last quarter, Inovio Pharmaceuticals, Inc. reported earnings of -0.07 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Inovio Pharmaceuticals, Inc. revenue for the last quarter?

Inovio Pharmaceuticals, Inc. reported quarterly revenue of 0. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Inovio Pharmaceuticals, Inc. net income for the last quarter?

Inovio Pharmaceuticals, Inc. reported net income of -6.01 M for the last quarter. The previous quarter showed -19.68 M, which means net income changed by +69.45%.

How many employees does Inovio Pharmaceuticals, Inc. have?

As of the latest available data, Inovio Pharmaceuticals, Inc. has 112 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Inovio Pharmaceuticals, Inc. stock?

You can buy Inovio Pharmaceuticals, Inc. (INO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Inovio Pharmaceuticals, Inc. stock?

Investing in Inovio Pharmaceuticals, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the INO chart and related analysis on metatrader.com as part of your research.

Inovio Pharmaceuticals, Inc. - Common Stock

Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.

News